Navigation Links
Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
Date:6/13/2013

CAMBRIDGE, Mass., June 13, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled in a Phase 1/2 clinical trial of EPZ-6438 (E7438). The trial is designed to assess the safety, tolerability and pharmacokinetics of EPZ-6438 (E7438), an orally available, small molecule inhibitor for non-Hodgkin lymphoma patients who have a cancer-causing (oncogenic) point mutation in EZH2.

Epizyme is developing EPZ-6438 (E7438) in partnership with Eisai Co., Ltd. In April 2011, the two companies announced a worldwide partnership to discover, develop and commercialize therapeutics targeting EZH2, with Epizyme retaining an opt-in right to co-develop, co-commercialize and share profits with Eisai on licensed products in the United States. As a result of the first patient enrollment in this trial, Epizyme earned a $6 million milestone payment from Eisai.

About EZH2 Cancers

EZH2 is a histone methyltransferase (HMT) that can become oncogenic and cause non-Hodgkin lymphoma and solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are mainly associated with oncogenic EZH2 mutations. Currently, there are no therapies approved specifically for the treatment of non-Hodgkin lymphoma associated with an EZH2 point mutation.

About Epizyme, Inc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of en
'/>"/>

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Epizyme, Inc. Announces Pricing of Initial Public Offering
2. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Epizyme to Partner to Develop DOT1L Companion Diagnostic
4. Epizyme to Present at Upcoming Conferences in February
5. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
6. Barts Hospital, London enrolls first patients in ROX Medicals CONTROL-HTN resistant hypertension trial
7. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
8. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
9. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
10. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
11. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 27, 2015 RnRMarketResearch.com ... market research report to its store. This report ... therapeutic pipeline. The report "Corneal Ulcers - Pipeline ... therapeutic development for Corneal Ulcers. Corneal Ulcers are ... bacterial infections, viral infections & fungal infections. The ...
(Date:2/26/2015)... , Feb. 26, 2015  AbbVie (NYSE: ... abstracts of studies in its neuroscience and oncology ... the 67 th American Academy of Neurology ... , from April 18-25. The accepted abstracts feature ... in addition to investigational treatments in AbbVie,s pipeline. ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  IRIDEX Corporation ... release its fourth quarter and full year 2014 financial results ...   In conjunction with the release, the Company will host ... p.m. Eastern Time on Thursday, March 5, 2015 ... business developments. Interested parties may access the live ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... Nationally-acclaimed researcher and award-winning author Dr. Cynthia C. Chernecky ... on Cancer Nursing Research that silver treated IV connectors ... to prevent. After testing antimicrobial effectiveness ... coated or silver impregnated fluid pathway components, Dr. Chernecky, ...
... 2011 Today, Smith & Nephew, Inc. (LSE: SN; ... with famed sports icon and humanitarian Billie Jean King ... with a Smith & Nephew product. One year ago, ... Nephew,s LEGION knee with the company,s exclusive VERILAST™ Technology, ...
Cached Medicine Technology:Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2Sports Icon Billie Jean King Gets Back in the Game with Help from New Knees 2Sports Icon Billie Jean King Gets Back in the Game with Help from New Knees 3Sports Icon Billie Jean King Gets Back in the Game with Help from New Knees 4
(Date:3/1/2015)... 01, 2015 Indiana Fiber Network, ... Provider, announces NewWays Networking, LLC (NewWays) selected IFN ... with IFN, NewWays is well positioned to scale ... for Internet bandwidth in rural parts of Indiana,” ... to Cory Childs IFN Enterprise Sales Manager, IFN ...
(Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located ... special discount to new members. Now through the end ... month contract will receive their fourth month half off. ... $440. The three month contract is only $264, dropping ... fourth month comes in at only $55. The special saves ...
(Date:2/28/2015)... 28, 2015 In a recent episode ... of Game Change Athlete Development Services and ... the benefits of athlete development and player engagement during ... unique challenges that athletes face and how off-field activities ... , Fletcher became involved in athlete development issues while ...
(Date:2/28/2015)... February 28, 2015 The Classic ... offering a new special. Throughout all of March ... , This service can help overall ... and pain. Patients may notice certain symptoms that suggest ... These symptoms include: , 1.    Pain, clicking, and popping ...
(Date:2/28/2015)... Indosoft Inc , developers of ... are pleased to announce the development of Q-Suite 5.9. ... versions of Q-Suite, this new version will include enhancements ... new features to the leading edge call center software. ... will add features to enhance security and protection. Administrators ...
Breaking Medicine News(10 mins):Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... , , ANAHEIM, Calif., ... the treatment capabilities of the Axxent(R) Electronic Brachytherapy, eBx(TM), System with ... the safety and feasibility for the treatment of non-melanoma skin cancers ... (AAPM) Meeting. The Company also announced that the first skin ...
... , , INDIANAPOLIS, July 27 ... advancing lung cancer treatment. On the heels of new FDA ... treatment for nonsquamous non-small cell lung cancer (NSCLC) in the maintenance ... cancer studies at the 13th World Conference on Lung Cancer (WCLC) ...
... , IRVINE, Calif., July 27 Accenx ... that its integration of BayCare Health System,s RxHistory ... questioning patient medication history and more time treating the patient. BayCare plans ... project,s end. , , In a business where ...
... , DOYLESTOWN, Pa., July 27 Prescient ... of the Year Award from Frost & Sullivan for Atherosclerosis Lesion ... related to heart attacks using the vProtect(TM) Luminal Shield. , ... occur when so-called "vulnerable" plaques rupture, releasing cholesterol and cellular debris ...
... , , INDIANAPOLIS, July 27 ... of 50 In d i a n a ... es to Watc h . ... Foundation, is sponsored by the Indiana Economic Development Corporation and its Small Business Development ...
... 27 SETO Holdings, Inc. (Pink Sheets: SETO) is pleased to ... hearing center in Virginia at 10120 West Broad Street, Suite G, ... hearing center in Montgomery Village (Gaithersburg), Maryland (18572 Office Park Drive). ... about September 1, 2009. , , ADVANCED is ...
Cached Medicine News:Health News:Xoft Expands Cancer Treatment Platform With Launch of Skin Cancer Electronic Brachytherapy Trial at AAPM Meeting 2Health News:Xoft Expands Cancer Treatment Platform With Launch of Skin Cancer Electronic Brachytherapy Trial at AAPM Meeting 3Health News:Xoft Expands Cancer Treatment Platform With Launch of Skin Cancer Electronic Brachytherapy Trial at AAPM Meeting 4Health News:Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting 2Health News:Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting 3Health News:Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting 4Health News:Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting 5Health News:Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting 6Health News:Accenx Information Exchange Platform Live With BayCare's RxHistory - Goal to Reach 8,200 Users 2Health News:Prescient Medical Receives Frost & Sullivan Product Innovation of the Year Award 2Health News:Prescient Medical Receives Frost & Sullivan Product Innovation of the Year Award 3Health News:SynCare, LLC Honored as Indiana Company to Watch 2Health News:SETO Holdings, Inc. Enters Into Two Additional Leases for Two New Hearing Centers in Maryland and Virginia 2
... anesthesia., ,Whether you need a machine ... theater or as a complete machine with ... product family allows you to choose the ... models, you have the flexibility to integrate ...
... level of excellence and economy., ,The ... system with basic ventilation at a moderate ... of the Aestiva/5 Anesthesia System - open ... it features a configurable version of Datex-Ohmeda's ...
... Carestation was developed using Datex-Ohmedas unique ... and continuous collaboration with clinicians. Clinicians ... anesthesia carestation that features advanced anesthesia ... patient monitoring, and Deio care information ...
... Strands® Absorbent Wound Dressing is a sterile, single ... moist wound dressing applications. The synthetic matrix ... the wound contours, and entraps slough and necrotic ... The strands of the matrix are bound ...
Medicine Products: